Neumora Therapeutics, Inc.
NMRA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.38
KIRA · Stoqly’s AI analyst, in plain words
- Neumora Therapeutics, Inc. lost $237M in fiscal 2025.
- Neumora Therapeutics, Inc. has $128M more cash than debt.
Market cap
$70.3M
P/E
—
Revenue
—
Net income
−$237M
Free cash flow
—
Operating margin
—
Neumora Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$237M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Neumora Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Neumora Therapeutics, Inc.
- CIK
- 0001885522
Neumora Therapeutics, Inc. · NMRA
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | −$131M | −$236M | −$244M | −$237M |
| Diluted EPS | −$4.81 | −$3.63 | −$1.53 | −$1.45 |
| Cash | ||||
| Cash from operations | −$115M | −$163M | −$183M | −$206M |
| Capital expenditure | $0.5M | $0.1M | — | — |
| Free cash flow | −$115M | −$163M | — | — |
| Share count change | — | 139.0% | 145.1% | 2.5% |
| Debt and strength | ||||
| Cash and short-term investments | $372M | $454M | $308M | $183M |
| Debt incl. finance leases | — | — | $0.0M | $54.5M |
| Shareholders' equity | −$447M | $469M | $287M | $104M |
| Current ratio | 16.4x | 19.0x | 10.5x | 5.9x |
| Interest coverage | — | — | — | −120.0x |
| Returns and quality | ||||
| Return on equity | — | −2,123.0% | −64.5% | −121.2% |
| Return on tangible equity | — | −50.3% | −84.9% | −228.1% |
| Piotroski F-score | — | — | — | 1 |
| Altman Z'' | −16.1 | 16.1 | 0.6 | −22.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.1M
4 insiders
Of sales under plans
29%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Neumora Therapeutics, Inc. · NMRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.38 a share, the company is worth $70.3M.
Source: SEC EDGAR XBRL filings (CIK 0001885522). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.